Non-animal alternative testing are modern techniques which are extensively used in scientific research purposes including applications like that of drug development, chemical testing, cosmetic product testing, and others. Computer programs these days are equipped with advanced systems on the basis of immense chemical databases that can predict the toxicity of a chemical, which consequently reduces or eliminates the need for animal testing. Various technologies involved in non-animal alternative testing include high throughput technology, cell culture technology, omic technology, and others.
Forecast Analysis of the Global Non-Animal Alternative Testing Market
Growing cases of chronic diseases along with the adoption of unhealthy eating habits among people across the globe are expected to drive the growth of the market during the forecast period, 2021-2030. In addition, increasing ethical issues linked with the use of animals for product testing is further expected to bolster the growth of the non-animal alternative testing. Moreover, persistent enhancements in existing and new non-animal alternative testing products are expected to create ample opportunities for the growth of the market. However, lack of awareness about non-animal alternative testing is expected to impede the growth of the market in the upcoming years.
According to the report published by Research Dive, the global non-animal alternative testing market is expected to garner a revenue of $29,390.20 million by 2030, growing rapidly at a CAGR of 13.0% during the forecast period 2021-2030. The major players of the market include VITROCELL Systems GmbH, Biovit, Evotec SE, MB Research Laboratories, TARA Biosystems, Inc., Emulate, Inc., Bio-Rad Laboratories, Inc., Hurel Corporation, Abbott, TissUse GmbH, and many more.
Key Trends & Developments of the Non-animal Alternative Testing Market
The key companies operating in the industry are adopting various growth strategies & business tactics such as partnerships, collaborations, mergers & acquisitions, and launches to maintain a robust position in the overall market, which is subsequently helping the global non-animal alternative testing market to grow exponentially. For instance,
- In March 2021, CELLINK, a Swedish 3D bioprinter manufacturer, acquired MatTek Corporation, a US-based life science technologies company and a dominant leader in non-animal alternative drug testing model, in order to accelerate CELLINK’s existing product workflow and advance its research into animal cruelty-free cellular testing models.
- In August 2021, the U.S. Environmental Protection Agency (EPA), an independent executive agency of the United States federal government tasked with environmental protection matters, collaborated with Unilever, a British multinational consumer goods company, in order to inspect constructive ways to evaluate chemical risks associated with consumer products so as to reduce the dependence on the use of animals.
- In October 2021, SenzaGen AB, a Sweden-based biotechnology company specializing in immunology, technology and genomics, acquired VitroScreen, an Italy-based innovative contract research company, in order to accelerate SenZagen’s growth strategy and maximize its presence in the global non-animal alternative testing market.
COVID-19 Impact on the Market
The outbreak of coronavirus has had a positive impact on the growth of the global non-animal alternative testing market, owing to the prevalence of lockdowns in various countries across the globe. During lockdown researchers avoided working in a wet laboratories, in order to restrict themselves from making any contact with humans or animals during pre-clinical testing of the drugs for maximum safety, accuracy, and efficiency. Hence, the demand for non-animal alternative testing techniques like microarrays, exponentially increased due to its requirement of minimal human contact.
Most Profitable Region of the Market
The North America region is expected to dominate the global non-animal alternative testing market, and grow at a CAGR of 12.85% during the forecast period. Prevalence of chronic diseases and rising chronic cases in this region is expected to drive the growth of the market. In addition, huge presence of non-animal alternative testing companies in the region is further expected to stimulate the growth of the regional non-animal alternative testing market during the forecast period.